TI
KYMR icon

Trexquant Investment’s Kymera Therapeutics KYMR Stock Holding History

Trexquant Investment’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,680
Closed -$1.92M – 1910
2025
Q4 		$1.92M Sell
24,680
-48,244
-66% -$3.26M 0.02% 1004
2025
Q3 		$4.13M Buy
72,924
+22,261
+44% +$1M 0.04% 620
2025
Q2 		$2.21M Buy
+50,663
New +$1.74M 0.02% 853
2024
Q3 		– Sell
-117,328
Closed -$3.5M – 1718
2024
Q2 		$3.5M Sell
117,328
-44,787
-28% -$1.55M 0.05% 518
2024
Q1 		$6.52M Sell
162,115
-41,449
-20% -$1.48M 0.13% 220
2023
Q4 		$5.18M Buy
+203,564
New +$3.64M 0.12% 240
2022
Q1 		– Sell
-10,454
Closed -$664K – 1560
2021
Q4 		$664K Buy
+10,454
New +$609K 0.04% 526
2021
Q2 		– Sell
-6,380
Closed -$248K – 1313
2021
Q1 		$248K Buy
+6,380
New +$384K 0.02% 856

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Trexquant Investment's KYMR Position: Q1 2026 in Review

Trexquant Investment sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 24,680 shares — an estimated $1.92M sold.

Trexquant Investment first reported a position in KYMR in Q1 2021 and held it in 8 quarters. The position peaked at $6.52M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Trexquant Investment reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 24,680 Kymera Therapeutics shares in Q1 2026, an estimated $1.92M.
  • Trexquant Investment first reported a position in Kymera Therapeutics in Q1 2021 and held it in 8 quarters.
  • Trexquant Investment's Kymera Therapeutics position peaked at $6.52M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.